(NASDAQ: NTLA) Intellia Therapeutics's forecast annual revenue growth rate of 109.12% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Intellia Therapeutics's revenue in 2025 is $45,569,000.On average, 12 Wall Street analysts forecast NTLA's revenue for 2025 to be $5,977,694,084, with the lowest NTLA revenue forecast at $1,722,591,842, and the highest NTLA revenue forecast at $21,752,512,740. On average, 10 Wall Street analysts forecast NTLA's revenue for 2026 to be $4,714,598,178, with the lowest NTLA revenue forecast at $932,250,546, and the highest NTLA revenue forecast at $10,358,339,400.
In 2027, NTLA is forecast to generate $53,440,744,632 in revenue, with the lowest revenue forecast at $378,079,388 and the highest revenue forecast at $392,187,446,363.